Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

BACKGROUND: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus tremelimumab plus EP numerically...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M.J., Özgüroğlu, M., Ji, J.H., Garassino, M.C., Voitko, O., Poltoratskiy, A., Musso, E., Havel, L., Bondarenko, I., Losonczy, G., Conev, N., Mann, H., Dalvi, T.B., Jiang, H., Goldman, J.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161394/
https://www.ncbi.nlm.nih.gov/pubmed/35279527
http://dx.doi.org/10.1016/j.esmoop.2022.100408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161394/
https://www.ncbi.nlm.nih.gov/pubmed/35279527
http://dx.doi.org/10.1016/j.esmoop.2022.100408

Ejemplares similares